Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease  by Broeders, Nilufer & Abramowicz, Daniel
Letters to the Editor354
syndromes had significantly reduced levels of Gq pro-
tein: 60  12 vs. 107  8 densitometric units; P  0.001
(Student t test).
The decrease in the abundance of Gq protein
strengthens the defect in the intracellular signaling that
reduces vascular reactivity of Bartter and Gitelman syn-
dromes. The next step will be to establish whether theFig. 1. Western blot of Gq protein expression in monocytes of healthy
controls (lanes 1 and 5) and of patients with Bartter and Gitelman reduction of Gq is a result of decreased production or
syndromes (lanes 2, 3, and 4). increased degradation, as well as to evaluate the molecu-
lar basis for these changes.
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function at baseline [2]. Interestingly, gemfibrozil wasPeroxisome proliferator-
devoid of this side effect [2]. A recent prospective study
in hyperlipemic patients with normal renal function con-activated receptors (PPARs):
firmed that fenofibrate, but not gemfibrozil, induced a
significant rise of serum creatinine level [3]. Of note,Novel therapeutic targets in
hyperhomocysteinemia was associated with fenofibrate-
induced increase in creatinine level [3].renal disease
On pathophysiological ground, the activation of PPAR
results in a down-regulation of the expression of cyclo-
To the Editor: In their excellent review on peroxisome oxygenase 2 (COX-2) and a reduction in the production
proliferator-activated receptors (PPARs), Dr. Guan and of vasodilatory prostaglandins [4]. These events may ob-
Dr. Breyer indicate that fibrates bind to and activate viously account for fibrate nephrotoxicity.
PPAR, but they do not mention any renal adverse event How should these data influence the nephrologist’s
associated with the modulation of PPAR activity [1]. We practice? First, we believe that fenofibrate, bezafibrate,
would like to emphasize the fact that fibrates may lead and ciprofibrate should not be prescribed to patients
to renal dysfunction. Indeed, an analysis of 27 patients with renal dysfunction. Second, hyperhomocysteinemia
from our institution who developed an impairment of may counteract the benefits expected from the lipid-
renal function during fibrate therapy and a literature lowering action of these fibrates. This is consistent with
review of 24 papers that reported data on 2676 patients trials showing that gemfibrozil is the only fibrate that
taking fibrates lead us to conclude that therapy with allowed for significant reductions of cardiac events in
fenofibrate, bezafibrate, and ciprofibrate may induce re- both primary and secondary prevention trials.
nal dysfunction [2]. This side effect was observed in pa-
tients with either native kidneys or kidney transplants Nilufer Broeders and Daniel Abramowicz
Brussels, Belgiumand among those with either normal or impaired renal
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